The results of the ENESTg1 trial confirm the efficacy of imatinib, but not nilotinib, as a first-line treatment for gastrointestinal stromal tumours (GISTs) harbouring sensitizing mutations in KIT or PDGFRA. Nilotonib might prove to be beneficial in other subset of patients; however, there remains an urgent unmet need to address the GIST subtypes that are therapeutic orphans.
Pantaleo, M.A., Biasco, G. (2015). Gastrointestinal cancer: Management of GIST--go beyond imatinib: treat resistant subtypes. NATURE REVIEWS. CLINICAL ONCOLOGY, 12(8), 440-442 [10.1038/nrclinonc.2015.107].
Gastrointestinal cancer: Management of GIST--go beyond imatinib: treat resistant subtypes
PANTALEO, MARIA ABBONDANZA;BIASCO, GUIDO
2015
Abstract
The results of the ENESTg1 trial confirm the efficacy of imatinib, but not nilotinib, as a first-line treatment for gastrointestinal stromal tumours (GISTs) harbouring sensitizing mutations in KIT or PDGFRA. Nilotonib might prove to be beneficial in other subset of patients; however, there remains an urgent unmet need to address the GIST subtypes that are therapeutic orphans.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
